Opening Identifying and Targeting DNA Repair Defects in Cancer (Yale Cancer Center Grand Rounds)
Identifying and Targeting DNA Repair Defects in Cancer (Yale Cancer Center Grand Rounds)
- Length
- 59 min
- Level
- Graduate
- Recorded
- Yale University2024
Chapter 1 of 9: Before the lecture
Ganesan models tumor allele frequency and purity to separate true biallelic BRCA loss from bystander mutations.
BRCA1 and BRCA2 mutations shape both cancer risk and treatment, and Ganesan's Yale Cancer Center Grand Rounds talk traces them from biology to clinic. He starts with hereditary risk, then locates BRCA1 in homology-mediated double-strand break repair during S phase. PARP inhibitors exploit that defect through synthetic lethality, and resistance arises through reversion mutations that restore the reading frame or through 53BP1 loss. Ganesan then builds models of mutant allele frequency, tumor purity and loss of heterozygosity to call biallelic loss from sequencing data. A pan-cancer analysis follows, questioning whether diverse DNA repair genes belong in one therapeutic category; familiarity with genetics and DNA repair is assumed.
BRCA1 and BRCA2 mutations shape both cancer risk and treatment, and Ganesan's Yale Cancer Center Grand Rounds talk traces them from biology to clinic. He starts with hereditary risk, then locates BRCA1 in homology-mediated double-strand break repair during S phase. PARP inhibitors exploit that defect through synthetic lethality, and resistance arises through reversion mutations that restore the reading frame or through 53BP1 loss. Ganesan then builds models of mutant allele frequency, tumor purity and loss of heterozygosity to call biallelic loss from sequencing data. A pan-cancer analysis follows, questioning whether diverse DNA repair genes belong in one therapeutic category; familiarity with genetics and DNA repair is assumed.
Couch et al., Science 2013
Breast Can. Cons. NEJM 2021
Scully, Ganesan et al., Science 1996
Chen, Silver et al., Mol Cell 1998
Scully, Ganesan et al., Mol. Cell 1999
Venkitaraman, 2002, Cell

This lecture
Talk 6 of 26 of Yale Cancer Center Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in
Nature Vol 434 2005 (Bryant et al. / Farmer et al.)
Helleday et al., Cell Cycle 2005
Moser, Pais, et al., Nat Rev Clin Onc, 2022
New England Journal of Medicine 2009 phase 1 study
Ashworth, Cancer Res. 2008 / Jaspers et al., Cancer Disc.
Cancer Res. 2008 Dec 15;68(24):10021-3
Cancer Res. 2008 April 15; 68(8): 2581–2586
Nat. Struct. Mol. Bio., 2010
JMCB 2011
Nat Rev Clin Onc, 2022
Sokol, et al JCO PO 2020
PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers
Pan-cancer analysis of homologous recombination repair-associated gene alterations and genome-wide loss of heterozygosity
Olaparib for Metastatic Castration-Resistant Prostate Cancer